Skip to main content
. 2000 Sep 15;106(6):763–771. doi: 10.1172/JCI9180

Figure 8.

Figure 8

Antitumor effects of Ad.DF3-E1/CMV-TNF. MDA-MB-231 and MCF-7 tumor xenografts were grown subcutaneously in nude mice to volumes of 150–200 mm3. (a) Groups of mice (n = 5) bearing MDA-MB-231 tumors were injected intratumorally with PBS (open squares) or 108 pfu of Ad.DF3-E1/CMV-TNF (filled diamonds) on day 0. (b) Groups of mice (n = 5) bearing MCF-7 tumors were injected intratumorally with PBS (open squares), 108 pfu of Ad.CMV-TNF (filled squares), 108 pfu of Ad.DF3-E1/CMV-TNF (filled diamonds), or 108 pfu of Ad.DF3-E1/CMV-GFP (open triangles) on day 0. (c) Mice bearing MCF-7 tumors injected with Ad.DF3-E1/CMV-TNF were followed for more than 56 days. One mouse died on day 52 without any tumors. Of the remaining four mice, one exhibited tumor regrowth (open circles). This mouse was reinjected with 108 pfu of Ad.DF3-E1/CMV-TNF on day 105 (arrow). The results are expressed as fractional tumor volume (V/V0). Differences among the MDA-MB-231 treatment groups were not significant. MCF-7 tumors infected with Ad.DF3-E1/CMV-TNF were significantly smaller at day 35 than were those treated with Ad.CMV-TNF (P < 0.001) or Ad.DF3-E1/CMV-GFP (P < 0.01).